Alemtuzumab infusion is rarely associated with serious cardiac toxicity. We report a case of acute troponin-negative chest pain with dynamic T-wave changes, immediately following first infusion of alemtuzumab in a patient with multiple sclerosis. The chest pain and ECG (electrocardiogram) changes improved with cessation of alemtuzumab and conservative management. The presumed cause was infusion-associated cytokine release, but the precise mechanism is unknown.
LenihanDJAlencarAJYangD, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood2004; 104(3): 655–658.
2.
BasquieraALBerrettaARGarciaJJ, et al. Coronary ischemia related to alemtuzumab therapy. Ann Oncol2004; 15(3): 539–540.
3.
FerraroDCameraVVitettaF, et al. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. Neurology2018; 90(18): 852–854.
4.
KounisNGSoufrasGDTsigkasG, et al. Adverse cardiac events to monoclonal antibodies used for cancer therapy: the risk of Kounis syndrome. Oncoimmunology2014; 3: e27987.
